Company Overview
- Headquarters
- 2929 Arch St, Suite 600, Philadelphia PA
- Website
- cabalettabio.com
- Phone
- (267) 759-3100
- Employees
- 3
- Founded in
- 2017
- Industry
- BioTech/Drugs
Financials & Stats
Revenue
$50B
Who is Cabaletta Bio
Cabaletta Bio, headquartered in Philadelphia, Pennsylvania, is a clinical-stage biotechnology company. Founded in 2017, Cabaletta Bio employs 3 individuals. Cabaletta Bio specializes in developing engineered T cell therapies aimed at treating autoimmune diseases. Their focus is on creating treatments that offer a potentially curative solution, providing patients with deep and durable responses. Their research encompasses two primary strategies: CARTA, utilizing chimeric antigen receptor T cells, and CAART, employing chimeric autoantibody receptor T cells. Cabaletta Bio's pipeline includes candidates such as CABA-201, targeting systemic lupus erythematosus and myositis, DSG3-CAART for mucosal pemphigus vulgaris, and MuSK-CAART for MuSK myasthenia gravis. Cabaletta Bio's platform, known as CABA™, is designed to address a broad spectrum of autoimmune diseases, potentially revolutionizing the treatment landscape. Their innovative approaches aim to deliver lasting and profound therapeutic benefits for patients. Cabaletta Bio's headquarters and laboratories are located in Philadelphia, Pennsylvania. For more information, visit cabalettabio.com.
Company Leadership
Cabaletta Bio Industry Tags
Companies Similar to Cabaletta Bio
Analyze industry trends and opportunities by examining competitors and companies comparable to Cabaletta Bio, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 50M | Cambridge, MA | |||
| 50M | 59 | Foster City, CA | ||
| 50M | 74 | San Diego, CA | ||
| 50M | 181 | New Haven, CT | 2017 | |
| 50M | 58 | Carlsbad, CA |